Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

The anti-TL1A antibody allowed significantly more inflammatory bowel disease (IBD) patients to go into remission than those ...

More than half (62.7%) of respondents reported facing financial barriers to obtaining their IBD medication.

Ira Daniel Breite, MD, is a board-certified internist and gastroenterologist. He is an associate professor at the Icahn ...

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

The trial was investigating the use of vagus nerve stimulation (VNS) for inflammatory bowel disease (IBD), an autoimmune ...

ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...

ORLANDO -- Longer hospitalization for flares of inflammatory bowel disease (IBD) was linked to greater risk of subsequent ...

A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.

lead author of the IBD study Joseph participated in and an instructor at the Institute of Bioelectronic Medicine at the Feinstein Institutes for Medical Research. “If we can augment what signals ...